We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. (REGN) on Notes From The Beauty Contest’s Substack. In ...

Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market. The company recently entered ...

Going forward, Celltrion is expected to continue its current strategy, aiming to have a total of 23 biosimilar products by 2030, covering therapeutic areas such as immunology and oncology. Leveraging ...

The U.S. FDA’s decision to grant breakthrough device designation for Bivacor Inc.’s titanium total artificial heart (TAH) ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

Regeneron (REGN) performed poorly. REGN stock entered a prolonged downtrend, despite no major news that would explain the decline. Last Friday, May 30, Regeneron and its drug development partner ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced st ...

In trying to lead before the system could follow, 23andMe outpaced the very guardrails that might have legitimized it”: A ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.